JenaValve Technology is a medical device company that develops and manufactures transcatheter aortic valve replacement (TAVR) systems for treating patients with aortic valve disease. The company's TAVI systems use a porcine pericardial tissue and self-expanding nitinol frame with a transfemoral delivery system that does not require rapid pacing because of an anatomically-based locator fixation and dual sealing valve design. This provides ease of use, reduced risks of paravalvular regurgitation and durability of patient hemodynamic outcomes to patients. The company is currently in clinical development of its next-generation transfemoral TAVR system in both the U.S. and CE mark countries for treating patients with aortic stenosis and/or aortic regurgitation. JenaValve Technology is backed by several investors including Bain Capital Life Sciences, Andera Partners, Gimv, Legend Capital, NeoMed Management, RMM, Valiance Life Sciences and VI Partners.